1 / 29

ATILLA ERTAN, MD, FACP, AGAF, MACG - PowerPoint PPT Presentation

  • Uploaded on

ATILLA ERTAN, MD, FACP, AGAF, MACG. F.G.# 02020323-8. A 87 y/o male with a h/o mild fluctuating HTN & over 50 yrs GERD who was diagnosed as having S.S. Barrett’s esophagus with intramucosal ca & multifocal HGD on 07/22/03. MED: Aciphex, Lisinopril & ASA.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'ATILLA ERTAN, MD, FACP, AGAF, MACG' - umberto

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

F g 02020323 8 l.jpg
F.G.# 02020323-8

A 87 y/o male with a h/o mild fluctuating HTN & over 50 yrs GERD who was diagnosed as having S.S. Barrett’s esophagus with intramucosal ca & multifocal HGD on 07/22/03.

MED: Aciphex, Lisinopril & ASA.

PMH, PSH, SH, FH, ROS & PE: Essentially unremarkable.

Chest/abd./pelvic CT scan & esophageal EUS findings were c/w intramucosal Barrett’s cancer.

He was referred for PDT & performed on 08/23/03.

Slide4 l.jpg

F G # 02020323-8

Barrett’s Ca, T1N0MX, 8/23/2003

PDT, 8/23/2003

Post-PDT F/U EGD, 3/01/2004

Post-PDT F/U EGD, 2/03/2005

F g 02020323 85 l.jpg
F. G. # 02020323-8

S.S. Barrett’s with recurrent HGD


S/P HALO-360 ablation


F g 02020323 8 s p halo 90 ablation 12 04 2007 l.jpg
F. G. # 02020323-8S/P HALO-90 ablation, 12/04/2007

A p 01911497 4 l.jpg
A.P.# 01911497-4

A 47 y/o male with a more than 9 yrs h/o GERD & intermittent dysphagia who has had 6-7 episodes of food impaction within last 2 years. He has been diagnosed as having L.S. Barrett’s with HGD/LGD & eosinophilic esophagitis.

MED: Zegerid 40 mg BID

PMH/PSH & FH: Unremarkable.

SH: Married, IT technician, no tobacco, ETOH or IVDA.

ROS: Gained 40 lbs within last 10 yrs.

PE: Essentially unremarkable except moderate obesity.

LAB: Unremarkable CBC-diff, SMA-6 & other blood tests. Chest/abd CT scan


Case ap l.jpg
Case AP

Previous history of food impactions:

A p 01911497 4 l s barrett s esophagus e e with transient circular rings l.jpg
A.P. #01911497-4L.S. Barrett’s esophagus & E.E. with transient circular rings

Case ap10 l.jpg
Case AP

  • Pathology

Basal zone hyperplasia, increased eosinophils Luminal accumulation

of eosinophils

What would you do next l.jpg
What would you do next?

  • Stage:

  • T3N0M0 Esophageal Cancer

  • GEJxn Type II Tumor

Eosinophilic esophagitis ee barrett s esophagus l.jpg

  • “Barrett’s esophagus or esophageal adenocarcinoma has not been reported in patients with EE” (1,2).

  • “EE is not a disease characterized by mucosal ulceration or destruction. Therefore, it seems likely that the pathologic process of EE is different from that of GERD and that adenocarcinoma or squamous cancer of the esophagus are

    not the spectrum of EE, other than perhaps as coincidental occurences” (2).

    Natural history & long-term follow-up studies are needed to provide more information in this relation.

    1. Am J Gastroenterol, 101: 1900, 2006.

    2. Gastroenterology, 133: 1342, 2007.

D w s 1740111 8 l.jpg
D.W.S.# 1740111-8 HALO-360

A 37 y/o male with a 5 yrs h/o intermittent solid food dysphagia, food impaction episodes who had many related ER visits. He has had minimal GERD complaints between

these episodes. During one of these episodes, he came to TMH ER.

MED: None

ALL: Penn, shellfish

PMH/PSH: Unremarkable

SH: Married, lawyer, denied T, ETOH & IVDA

FH: Noncontributory

ROS/PE: Unremarkable

Emergent EGD & biopsy findings

D w s 1740111 816 l.jpg
D.W.S. # 1740111-8 HALO-360

Post food impaction 3-20-2003

Food impaction 3-20-2003

D w s 1740111 8 linear furrowing vertical lines white specks l.jpg
D.W.S. # 1740111-8 HALO-360 Linear furrowing, vertical lines & white specks

D w s 1740111 8 duodenal adenoma duodenal ulcer l.jpg
D.W.S. # 1740111-8 HALO-360 Duodenal adenoma Duodenal ulcer

Eosinophilic esophagitis ee l.jpg


___________________________________________________During the last decade, we saw a rapid increase of patients with esophageal intraepithelial eosinophilia who were thought to be GERD but who did not respond to GERD management. Subsequent studies showed that these patients had a “new “ disease termed EE which is a disease characterized by:

Symptoms including but not restricted to food impaction & dysphagia in adults , and feeding intolerance & GERD symptoms in children.

≥15 intraepithelial eosinophilis/HPF

Exclusion of other disorders associated with similar clinical, histological, or endoscopic features, especially GERD.


FIGERS; Gastroenterol 133:1342-63, 2007.

Endoscopic features associated with e e l.jpg


  • Unremarkable endoscopic mucosa & lumen.

  • Circular rings, transient or fixed, “feline esophagus”

  • Linear furrowing, vertical lines of the mucosa

  • Linear shearing/crepe paper mucosa with passage of endoscope or dilator

  • White exudates, white specks, nodules or granularity

  • Stricture/rings: proximal, middle, or distal.


    FIGERS: Gastroenterol, 133: 1342, 2007 (modified).

    * None of the features are pathogonomic of EE.

J m h 2096026 6 linear shearing l.jpg
J.M.H. # 2096026-6 HALO-360 Linear shearing

A e 2096036 5 circular rings feline esophagus l.jpg
A.E. # 2096036-5 HALO-360 Circular rings, “feline esophagus”

I e 3659813 1 barrett s islands e e with transient circular rings l.jpg
I.E. # 3659813-1 HALO-360 Barrett’s islands & E.E. with transient circular rings

Differential diagnosis of eosinophilic esophagitis l.jpg

Differential Diagnosis of Eosinophilic Esophagitis HALO-360


Crohn’s disease*

Connective tissue disorders*

Hypereosinophilia syndrome

Infections [herpes & candida]*

Drug sensitivity response

Eosinophilic gastroenteritis


*These diseases may have intraepithelial eosinophilia but less than

15/HPF in one or more biopsy specimens.

Allergy evaluation in patients with e e l.jpg

  • The majority of patients with EE is atopic based on the coexistence of atophic dermatitis, allergic rhinitis, and/or bronchial asthma & the presence of allergic antigen skin sensitization or measurement of plasma antigen-specific IgE.

  • 10%-50% of adults had peripheral eosinophilia.

  • Most patients improve on allergen-free diets.

  • Allergist consultation may be recommended.

    ClinGastroenterol Hepatol 3:1198-206, 2005.

    J Pediatr Gastroenterol Nutr 42:22-6, 2006.

Medical management of e e l.jpg

  • Removal of allergenic foods [diary, eggs, wheat, soy, peanuts, fish/shellfish], without unpredictive allergy testing, demonstrated significant efficacy (1). The elemental diet was very effective in severe cases with EE (1).

  • Only 16% of patients with EE showed symptomatic improvement with PPI treatment (2).

  • Systemic and topical corticosteroids resolve acute symptoms of EE. Fluticasone propionate 440 mcg BID for 6-8 weeks may be effective for induction therapy (3).

  • Endoscopic dilatation is useful in patients with fixed strictures/rings causing food impaction. However, the risk of mucosal tearing and perforation are relatively higher (4,5).

    1. Clin Gastroenterol Hepatol 4: 1097-102, 2006.

    2. Am J Gastroenterol 101: 1666-70, 2006.

    3. Gastrointest Endosc 63:3-12, 2006.

    4 & 5. Gastroenterology 127: 364-5, 2004; 133:1342, 2007.